GSK: innovative therapy designation granted in China

(CercleFinance.com) - GSK has announced that China has granted Breakthrough Therapy Designation (BTD) for Blenrep, in combination with bortezomib and dexamethasone, to treat relapsed or refractory multiple myeloma.


The decision aims to accelerate the development of therapies for serious diseases.

Hesham Abdullah, Vice President of GSK, said the designation underscores Blenrep's potential to redefine patient outcomes.

The BTD is based on the results of the DREAMM-7 trial, which showed significant improvements in progression-free survival compared with standard treatments.


Copyright (c) 2024 CercleFinance.com. All rights reserved.